医薬品リファレンス
Cobimetinib
Cobimetinib is a medicine in the class oncology. It is used for melanoma.
- 薬効分類: Oncology
- 効能・効果: melanoma
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01XE38
- 一般的な剤形
- 錠剤
- 一般的な規格
- 20 mg
- 既知の相互作用
- 49 (併用禁忌: 2 · 重大: 30 · 中等度: 10 · 軽度: 7)
- 商品名
- 3
- 国・市場
- 3
何に使われるか
作用のしくみ
Cobimetinib is a reversible inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway that promotes cellular proliferation.
成人の通常用量（添付文書の要約）
Unresectable or metastatic melanoma with BRAF V600E or V600K mutation (with vemurafenib) and histiocytic neoplasms: 60 mg (three 20 mg tablets) orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm: teratogenic and embryotoxic in rats at exposures similar to human doses; no human data. Avoid in pregnancy; use effective contraception during treatment and for 2 weeks after the last dose (US label; UK label: 3 months).
- 授乳
- Unsafe No human milk data. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 2 weeks after the last dose.
報告されている副作用
- Diarrhea
- Photosensitivity reaction
- Nausea
- Pyrexia
- Vomiting
注意が必要な方
- New primary malignancies (cutaneous and non-cutaneous): monitor before, during and for up to 6 months after the last dose.
- Hemorrhage, including major hemorrhage, can occur; monitor for bleeding.
- Cardiomyopathy: evaluate LVEF before treatment, after one month, then every 3 months; safety not established with decreased LVEF.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (49)
- Cobimetinib + Efavirenz Contraindicated
- Cobimetinib + Posaconazole Contraindicated
- Amobarbital + Cobimetinib Major
- Apalutamide + Cobimetinib Major
- Aprepitant + Cobimetinib Major
- Bosentan + Cobimetinib Major
- Carbamazepine + Cobimetinib Major
- Chloramphenicol + Cobimetinib Major
- Ciprofloxacin + Cobimetinib Major
- Clarithromycin + Cobimetinib Major
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Cobimetinibの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Cobimetinib used for?
Cobimetinib is a medicine in the class oncology. It is used for Melanoma.
What side effects have been reported with Cobimetinib?
Diarrhea, Photosensitivity reaction, Nausea, Pyrexia, Vomiting.
Can Cobimetinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: teratogenic and embryotoxic in rats at exposures similar to human doses; no human data. Avoid in pregnancy; use effective contraception during treatment and for 2 weeks after the last dose (US label; UK label: 3 months). Breastfeeding: Unsafe. No human milk data. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 2 weeks after the last dose.
What does Cobimetinib interact with?
MediHelp lists 49 known interactions for Cobimetinib. Contraindicated: 2 · Major: 30 · Moderate: 10 · Minor: 7. The most serious include Efavirenz, Posaconazole, Amobarbital.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
